Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effect of PTH134 at Increasing Doses in Healthy Postmenopausal Subjects
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00676312 |
Recruitment Status :
Completed
First Posted : May 13, 2008
Last Update Posted : December 11, 2008
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Postmenopausal Osteoporosis | Drug: PTH134 | Phase 1 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 32 participants |
Allocation: | Randomized |
Intervention Model: | Crossover Assignment |
Masking: | Triple (Participant, Care Provider, Investigator) |
Primary Purpose: | Treatment |
Official Title: | A Partially-Blinded, Randomized, Placebo and Active Controlled, Ascending Single-Dose Crossover Phase I Study to Explore the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effects of PTH134 Formulated With Different Concentrations of 5-CNAC in Healthy Postmenopausal Women |
Study Start Date : | May 2008 |
Actual Primary Completion Date : | August 2008 |

Arm | Intervention/treatment |
---|---|
Experimental: 1
Cross-over treatment with increasing doses of PTH134, placebo and active comparator.
|
Drug: PTH134
Other Name: teriparatid |
- •Safety and tolerability of ascending single doses of PTH134 over 24 hours as compared to baseline. •Pharmacokinetics after ascending single doses of PTH134, including comparison with reference drug Forteo 20 µg sc over 24 hours.
- •Assessment of PK from PTH134 formulations over 24 hours. •Assessment of the pharmacodynamic profile of serum ionized calcium, total serum calcium, bone biomarkers with reference drug Forteo 20 µg and placebo over 24 hours.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 40 Years to 70 Years (Adult, Older Adult) |
Sexes Eligible for Study: | Female |
Inclusion Criteria:
- Healthy postmenopausal female subjects, 40 to 70 years of age and in good health as determined by past medical history, physical examination, vital signs, electrocardiogram, and laboratory tests at screening
- Body mass index (BMI) within the range of 19 to 32.
Exclusion Criteria:
- Smokers who report cigarette use of >= 5 cigarettes per day.
- Use of any prescription drugs or over-the-counter (OTC) medication (vitamins, herbal supplements, dietary supplements) started within the last month prior to screening.
- Previous osteoporosis treatment
- History of drug or alcohol abuse within the 12 months prior to dosing or evidence of such abuse
Other protocol-defined inclusion/exclusion criteria may apply

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00676312
Switzerland | |
Novartis Investigative site | |
Basel, Switzerland |
Principal Investigator: | Novartis Pharma AG, Basel | Novartis Pharma AG, Basel |
Responsible Party: | External Affairs, Novartis |
ClinicalTrials.gov Identifier: | NCT00676312 |
Other Study ID Numbers: |
CPTH134A2101 |
First Posted: | May 13, 2008 Key Record Dates |
Last Update Posted: | December 11, 2008 |
Last Verified: | December 2008 |
Osteoporosis parathyroid hormone pharmacodynamic pharmacokinetic |
Osteoporosis Osteoporosis, Postmenopausal Bone Diseases, Metabolic |
Bone Diseases Musculoskeletal Diseases Metabolic Diseases |